Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation

• Published in: The journal of clinical endocrinology and metabolism 2002-03, Vol.87 (3), p.1427-1430
• Main Authors: GRÜNDKER, Carsten, GÜNTHERT, Andreas R, MILLAR, Robert P, EMONS, Günter
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Cell Division - drug effects; Cell Division - physiology; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - pathology; Female; Female genital diseases; Fundamental and applied biological sciences. Psychology; Gonadotropin-Releasing Hormone - analogs & derivatives; Gonadotropin-Releasing Hormone - pharmacology; Gynecology. Andrology. Obstetrics; Hormones and neuropeptides. Regulation; Humans; Hypothalamus. Hypophysis. Epiphysis. Urophysis; Medical sciences; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Receptors, LHRH - agonists; Receptors, LHRH - metabolism; Triptorelin Pamoate - pharmacology; Tumor Cells, Cultured; Tumors; Vertebrates: endocrinology
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.87.3.1427

Recently it was shown that a second GnRH system exists in primates. This study was conducted to investigate whether or not the receptor specific for GnRH type II is expressed in human endometrial and ovarian cancer cells and whether or not GnRH-II has effects on tumor cell proliferation. Expression of GnRH-II receptor mRNA in endometrial and ovarian cancer cell lines was demonstrated using RT-PCR and Southern blot analysis. The proliferation of these cell lines was dose- and time-dependently reduced by native GnRH-II. These effects were significantly more potent than the anitproliferative effects of equimolar doses of GnRH-I agonist Triptorelin (p